To test the effects of CCL2 upon initiation of HIV brain disease by an alternate approach, we employed the compound bindarit that inhibits transcription of CCL2 through interference with NFκB activation at the CCL2 promoter35. The gene discussed is NFKB1; the disease is brain disorder.